

ISSN:2347-4742



Review Article
Journal of Pharmaceutical and Biomedical
Analysis Letters

www.pharmaresearchlibrary.com/jpbmal



A Brief Description on Cancer and Natural Remedies with Potential Anti-cancer Activity: A Review

Amita Pandey* and ShaliniTripathi

Rameshwaram Institute of Technology and Management, Sitapur Road, Lucknow (U.P.), India

Abstract

At present times, Herbal remedies occupy an important position for being the paramount sources of drug discovery, irrespective of its categorized groups in which including herbs, Shrubs or trees. Plants have been indispensable in treating diverse form of diseases including cancer. Cancer is not just one disease but many diseases. There are more than 100 different types of cancer the plant based drug discovery resulted mainly in the development of anticancer agents including plants (vincristine, vinblastine, etoposide, paclitaxel, camptothecin, topotecan and irinotecan), marine organisms (citarabine, aplidine and dolastatin 10) and micro-organisms (dactinomycin, bleomycin and doxorubicin).

Key words: Cancer, Herbal remedies, Dietary remedies, Marine remedies, Micro-organism as a source of anti-cancer drugs.

Contents

| | |
|------------------------------|----|
| 1. Introduction | 85 |
| 2. Conclusion | 93 |
| 3. Acknowledgement | 93 |
| 4. References | 93 |

***Corresponding author**

Amita Pandey
 E-mail: pandey.amita2012@gmail.com
 MS.ID: PRL2014-JPBMAL1955



PAPER-QR CODE

Copyright © 2014, JPBMAL All Rights Reserved

1. Introduction

Cancer is a dreadful disease characterized by the irregular proliferation of the cells. As a cell progresses from normal to cancerous, the biological imperative to survive and perpetuate drives fundamental changes in cells behaviour. So the actual cause of the disease in different sections is still to be explored clearly. Cancer is thus, a class of disease, classified by the type of cell that is initially affected. Today's global scenario indicates that breast cancer and colorectal cancer is the most prominent cancer in case of women and men. To combat cancer United States national cancer institute has undergone 2069 anticancer clinical trials, in which over 150 drug combination have been successfully recorded against cancer. There is no one definition that describes all cancers. They are a large family of diseases which form a subset of neoplasms, which show some features that suggest of malignancy. A neoplasm or tumour is a group of cells that have undergone unregulated growth, and will often form a mass or lump, but may be distributed diffusely.^[3,4]

Causes of cancer

Cancers are primarily an environmental disease with 90–95% of cases attributed to environmental factors and 5–10% due to genetics. *Environmental*, as used by cancer researchers, means any cause that is not inherited genetically, not merely pollution. Common environmental factors that contribute to cancer death include

tobacco(25–30%), diet and obesity (30–35%), infections (15–20%), radiation (both ionizing and non-ionizing, up to 10%), stress, lack of physical activity, and environmental pollutants.

It is nearly impossible to prove what caused a cancer in any individual, because most cancers have multiple possible causes. For example, if a person who uses tobacco heavily develops lung cancer, then it was probably caused by the tobacco use, but since everyone has a small chance of developing lung cancer as a result of air pollution or radiation, then there is a small chance that the cancer developed because of air pollution or radiation.^[10,11]

Sign and Symptoms of cancer

Fever :Fever is very common with cancer, but it more often happens after cancer has spread from where it started, fast breathing, and abnormal lung sounds heard through a stethoscope,

Weight loss: Unexplained weight loss,this happens most often with cancers of the pancreas, stomach, oesophagus (swallowing tube), or lung.

Fatigue: Fatigue may happen early, though, in some cancers, like leukemia. Some colon or stomach cancers can cause blood loss that's not obvious. This is another way cancer can cause fatigue.

Pain: Pain may be an early symptom with some cancers like bone cancers or testicular cancer.Back pain can be a symptom of cancer of the colon, rectum, or ovary. Most often, pain due to cancer means it has already spread (metastasized) from where it started.

Skin changes:Along with cancers of the skin, some other cancers can cause skin changes that can be seen. These signs and symptoms include:

Darker looking skin (hyperpigmentation)

Yellowish skin and eyes (jaundice)

Reddened skin (erythema)

Itching (pruritis)

Excessive hair growth

Long-term constipation: Diarrhoea, or a change in the size of the stool may be a sign of colon cancer. Pain when passing urine, blood in the urine, or a change in bladder function (such as needing to pass urine more or less often than usual) could be related to bladder or prostate cancer.Skin cancers may bleed and look like sores that don't heal.

Sore: A long-lasting sore in the mouth could be an oral cancer. This should be dealt with right away, especially in people who smoke, chew tobacco, or often drink alcohol. Sores on the penis or vagina may either be signs of infection or an early cancer, and should be seen by a health professional.

White patches/white spot: White patches inside the mouth and white spots on the tongue may be leukoplakia. Leukoplakia is a pre-cancerous area that's caused by frequent irritation. It's often caused by smoking or other tobacco use. People who smoke pipes or use oral or spit tobacco are at high risk for leukoplakia. If it's not treated, leukoplakia can become mouth cancer. Any long-lasting mouth changes should be checked by a doctor or dentist right away.

Coughing and unusual bleeding: Unusual bleeding can happen in early or advanced cancer. Coughing up blood in the sputum (phlegm) may be a sign of lung cancer. Blood in the stool (which can look like very dark or black stool) could be a sign of colon or rectal cancer. Cancer of the cervix or the endometrium (lining of the uterus) can cause abnormal vaginal bleeding. Blood in the urine may be a sign of bladder or kidney cancer. A bloody discharge from the nipple may be a sign of breast cancer.

Lumps and nodes: A lump or thickening in breast, lymph nodes and testis may be an early or late sign of cancer, especially if it has grown in size. Some breast cancers show up as red or thickened skin rather than the expected lump.

Indigestion or swallowing:

Indigestion or swallowing problems that don't go away may be signs of cancer of the oesophagus (the swallowing tube that goes to the stomach), stomach, or pharynx (throat). But like most symptoms on this list, they are most often caused by something other than cancer.A cough that does not go away may be a sign of lung cancer. Hoarseness can be a sign of cancer of the voice box (larynx) or thyroid gland.^[2]

Types of cancer

Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer that begins in melanocytes of the skin is called melanoma.

Cancer types can be grouped into broader categories. The main categories of cancer include:

Carcinoma - cancer that begins in the skin or in tissues that line or cover internal organs. There are a number of subtypes of carcinoma, including adenocarcinoma, basal cell carcinoma,

Sarcoma - cancer that besquamous cell carcinoma, and transitional cellcarcinoma.gins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue.

Leukemia - cancer that starts in blood-forming tissue such as the bone marrow and causes large numbers of abnormal blood cells to be produced and enter the blood.

Lymphoma and myeloma - cancers that begin in the cells of the immune system.

Central nervous system cancers - cancers that begin in the tissues of the brain and spinal cord.

Germ cell tumor: Cancers derived from pluripotent cells, most often presenting in the testicle or the ovary (seminoma and dysgerminoma, respectively).

Blastoma: Cancers derived from immature "precursor" cells or embryonic tissue. Blastomas are more common in children than in older adults.^[9]

Stages of cancer

Overall Stage Grouping is also referred to as Roman Numeral Staging. This system uses numerals I, II, III, and IV (plus the 0) to describe the progression of cancer.

Stage 0: carcinoma in situ.

Stage I: cancers are localized to one part of the body. Stage I cancer can be surgically removed if small enough.

Stage II: cancers are locally advanced. Stage II cancer can be treated by chemo, radiation, or surgery.

Stage III: cancers are also locally advanced. Whether a cancer is designated as Stage II or Stage III can depend on the specific type of cancer; for example, in Hodgkin's disease, Stage II indicates affected lymph nodes on only one side of the diaphragm, whereas Stage III indicates affected lymph nodes above and below the diaphragm. The specific criteria for Stages II and III therefore differ according to diagnosis. Stage III can be treated by chemo, radiation, or surgery

Stage IV: cancers have often metastasized, or spread to other organs or throughout the body. Stage IV cancer can be treated by chemo, radiation, or surgery.^[5,6]

Herbal Remedies with Potential Anti-Cancer Activity

The history of plant as source of anti-cancer agents started in earnest in the 1950s with the discovery and development of the vinca alkaloids (vinblastine and vincristine) and the isolation of the cytotoxic podophyllotoxins. Vinca alkaloid was responsible for an increase in the cure rates for Hodgkin's disease and some forms of leukemia^[12]. Vincristine inhibits microtubule assembly, inducing tubulin self-association into coiled spiral aggregates^[13]. Etoposide is an epipodophyllotoxin, derived from the mandrake plant *Podophyllum peltatum* and the wild chervil *Podophyllum emodi*^[14]. It has also significant activity against small-cell lung carcinoma^[15]. Etoposide is a topoisomerase II inhibitor, stabilizing enzyme-DNA cleavable complexes leading to DNA breaks^[16]. The taxanes paclitaxel and docetaxel has been show antitumor activity against breast, ovarian and other tumor types in the clinic trial. Paclitaxel stabilizes microtubules and leading to mitotic arrest^[17]. In addition, the camptothecin derivatives irinotecan and topotecan, have shown significant antitumor activity against colorectal and ovarian cancer respectively^[18, 19]. These compounds were initially obtained from the bark and wood of *Nyssaceae* *Camptotheca acuminata* and act by inhibiting topoisomerase I^[20]. The taxanes and the camptothecins are presently approved for human use in various countries. Rohitukine the plant alkaloid, isolated from the leaves and stems of *Dysoxylum biceciferum* (Maliaceae)^[21, 22]. Synthetic flavone derived from rohitukine, Flavopiridol representing the first cyclin-dependent kinase inhibitor to enter the clinical trial^[23]. The mechanism of action involves interfering with the phosphorylation of cyclin-dependent kinases and arrest cell-cycle progression at growth phase G1 or G2^[24, 25]. Homoharringtonine an alkaloid isolated from the Chinese tree *Cephalotaxus harringtonia* (*Cephalotaxaceae*)^[26]. The mechanism of action is the inhibition of protein synthesis and blocking cell-cycle progression^[27]. It has shown efficacy against various leukemias^[28]. A lung-cancer-specific antineoplastic agent 4-*Ipomeanol* is isolated from the sweet potato *Ipomoea batata* (*Convolvulaceae*)^[29]. The mechanism of action is converted into DNA-binding metabolites upon metabolic activation by cytochrome P450 enzymes that are present in cells of the lung^[30]. DNA topoisomerase I inhibitor -lapachone, that induces cell-cycle delay at G1 or S (synthesis) phase before inducing either apoptotic or necrotic cell death in a variety of human carcinoma cells, including ovary, colon, lung, prostate and breast^[31]. Beside this there are so many plants which are used in cancer; following enlist the plant which prevent and target for future studies as potential anticancer agent (Table.1)

Table 1: Herbal remedies used as anti-cancer^[32]

| S.No | Plant Species | Family | Plant Part |
|------|-------------------------------|-----------------|--------------------------|
| 1. | <i>Salvia officinalis</i> | Labiatae | Leaves |
| 2. | <i>Viscum album</i> | Loranthaceae | Leaves |
| 3. | <i>Combretum caffrum</i> | Combretaceae | Bark |
| 4. | <i>Melaleuca alternifolia</i> | Myrtaceae | Leaves |
| 5. | <i>Lavandula angustifolia</i> | Labiatae | Leaves |
| 6. | <i>Aglaia foveolata</i> | Meliaceae | Fruit |
| 7. | <i>Maytenus serrata</i> | Celastraceae | Seed |
| 8. | <i>Tabebuia impetiginosa</i> | Bignoniaceae | Stem bark and trunk wood |
| 9. | <i>Tabebuia rosea</i> | Bignoniaceae | Stem bark and trunk wood |
| 10. | <i>Tabebuia serratifolia</i> | Bignoniaceae | Stem bark and trunk wood |
| 11. | <i>Dipteryx odorata</i> | Fabaceae | Seed |
| 12. | <i>Thapsiagarganica</i> | Apiaceae | Fruit |
| 13. | <i>Indigofera tinctoria</i> | Leguminosae | Aerial part |
| 14. | <i>Matricaria chamomilla</i> | Asteraceae | Flower |
| 15. | <i>Erythroxylum pervillei</i> | Erythroxylaceae | Root |

| | | | |
|-----|--|-----------------|---------------------|
| 16. | Broussonetiapapyrifera | Urticaceae | Entire |
| 17. | Cyclopiaintermedia | Fabaceae | Leaves |
| 18. | Scutellariae radix, Scutellariaeindica | Labiatae | Root |
| 19. | Physalisphiladelphica | Solanaceae | Seed |
| 20. | Dysoxylumnectariferum | Meliaceae | Stem bark |
| 21. | Aristoteliachilensis | Elaeocarpaceae | Leaf and Stem |
| 22. | Cyathostemmaargentum | Annonaceae | Root |
| 23. | Epimediumhunanense | Berberidaceae | Aerial parts |
| 24. | Croton urucurama | Euphorbiaceae | Bark |
| 25. | Epilobiumhirsutum | Onagraceae | Entire |
| 26. | Pleionebulbocodioides | Orchidaceae | Tuber |
| 27. | Cassia quinquangulata | Caesalpiniaceae | Root |
| 28. | Begonia glabra | Begoniaceae | Entire |
| 29. | Celastrusorbiculatus | Celastraceae | Entire |
| 30. | Croton draco | Euphorbiaceae | Aerial parts |
| 31. | Smilax sieboldii | Liliaceae | Entire |
| 32. | Ximenia Americana | Olaceae | Root |
| 33. | Maytenusemarginata | Celastraceae | Entire |
| 34. | Sarcandra glabra | Choranthaceae | Entire |
| 35. | Salvia plebeian | Labiatae | Aerial |
| 36. | Scutellariabarbata | Labiatae | Entire |
| 37. | Ocoteacaparrapi | Lauraceae | Essential oil |
| 38. | Caraganacuneata | Leguminosae | Leaf |
| 39. | Croton flavens | Euphorbiaceae | Leaf |
| 40. | Euphorbia heterophylla | Euphorbiaceae | Stem |
| 41. | Echitesvucatanensis | Apocynaceae | Latex |
| 42. | Thevetiaahouia | Apocynaceae | Leaf and Stem |
| 43. | Thevetiagaumeri | Apocynaceae | Leaf and Stem |
| 44. | Thevetiaperuciana | Apocynaceae | Leaf and Stem |
| 45. | Euphorbia ebracteolata | Euphorbiaceae | Aerial parts |
| 46. | Dioscoreacollettii | Dioscoreaceae | Rhizome |
| 47. | Juglansmandshurica | Juglandaceae | Root |
| 48. | Maackiatenuifolia | Leguminosae | Root |
| 49. | Juncusacutus | Juncaceae | Leaf |
| 50. | Hedyotischrysotricha | Rubiaceae | Entire |
| 51. | Arisaemaerubescens | Araceae | Root |
| 52. | Leptadenia hastate | Asclepiadaceae | Bark |
| 53. | Viscumcalcaratum | Loranthaceae | Entire |
| 54. | Aphanamixispolystachya | Meliaceae | Stembark |
| 55. | Pratianummularia | Campanulaceae | Entire |
| 56. | Aeonium arboretum | Crassulaceae | Leaf |
| 57. | Ocoteafoetens | Lauraceae | Branchlets |
| 58. | Maytenuscanariensis | Celastraceae | Fruit juice |
| 59. | Sedum alboroseum | Crassulaceae | Entire |
| 60. | Euphorbia micractina | Euphorbiaceae | Entire |
| 61. | Euphorbia prolifera | Euphorbiaceae | Latex |
| 62. | Scirpusholoschoenus | Cyperaceae | Inflorescence |
| 63. | Dillenia suffruticosa | Dilleniaceae | Fruit |
| 64. | Hypoxisrooperii | Hypoxiaceae | Tuber |
| 65. | Inulalinariaefolia | Compositae | Flowers |
| 66. | Ziziphusmauritiana | Rhamnaceae | Stem bark and Fruit |
| 67. | Adiantummacrophyllum | Pteridaceae | Entire |
| 68. | Thalictrumfabri | Ranunculaceae | Root |
| 69. | Scutellariaindica | Labiatae | Root |
| 70. | Hypericumjaponicum | Guttiferae | Entire |
| 71. | Cyatheaaurieii | Cyatheaceae | Shoot |

| | | | |
|------|---------------------------|-----------------|--------------|
| 72. | Fissistigmaoldhamii | Annonaceae | Stem |
| 73. | Monninaobtusifolia | Polygalaceae | Aerial parts |
| 74. | Coriolusversicolor | Polyporaceae | Fruitbody |
| 75. | Melastomamalabathricum | Melatomataceae | Flower |
| 76. | Carapaguianensis | Meliaceae | Seed oil |
| 77. | Swieteniahumilis | Meliaceae | Seed |
| 78. | Ficuspretoiae | Moraceae | Sap |
| 79. | Croton lechleri | Euphorbiaceae | Latex |
| 80. | Aster amellus | Compositae | Entire |
| 81. | Crassocephalumbojeri | Compositae | Entire |
| 82. | Echinopsgrijisii | Compositae | Root |
| 83. | Adeniumobesum | Apocynaceae | Leaf |
| 84. | Ipomeabatata | Convolvulaceae | Rhizome |
| 85. | Uncariatomentosa | Rubiaceae | Bark |
| 86. | Plantagoasiatica | Plantaginaceae | Leaf |
| 87. | Phymatosorusdiversifolium | Polydiaceae | Root |
| 88. | Rabdosiarubescens | Labiatae | Leaf |
| 89. | Salvia chinensis | Labiatae | Entire |
| 90. | Ganodermalucidum | Ganodermataceae | Fruitbody |
| 91. | Euphorbia kansui | Euphorbiaceae | Root |
| 92. | Echinopsatifolius | Compositae | Root |
| 93. | Euphorbia marginata | Euphorbiaceae | Entire |
| 94. | Ligustrumlucidum | Oleaceae | Seed |
| 95. | Phytolaccaesculenta | Phytolaccaceae | Root |
| 96. | Pinusparviflora | Pinaceae | Strobilus |
| 97. | Dysosmapleiantha | Berberidaceae | Root |
| 98. | Alnus japonica | Betulaceae | Wood |
| 99. | Ruellia tuberosa | Acanthaceae | Bark |
| 100. | Acacia xanthophloea | Leguminosae | Fruit |
| 101. | Lanneastuhlmannii | Anacardiaceae | Root |
| 102. | Maytenusobscura | Celastraceae | Leaf |
| 103. | Plicosepalussagittifolius | Loranthaceae | Branches |
| 104. | Piper latifolium | Piperaceae | Leaf |
| 105. | Morindacitrifolia | Rubiaceae | Root |
| 106. | Knematenuinervia | Myristicaceae | Stembark |
| 107. | Deeringiaamaranthoides | Amaranthaceae | Fruit |
| 108. | Cynanchumhancoekianum | Asclepiadaceae | Entire |
| 109. | Azadirachtaindica | Meliaceae | Leaf |
| 110. | Violabicuhyba | Myristicaceae | Seed |
| 111. | Sempervivumarmenum | Crassulaceae | Leaf |
| 112. | Sempervivumarvense | Crassulaceae | Leaf |
| 113. | Hippophaesalicifolia | Elaeagnaceae | Fruit |
| 114. | Hypoxisnyasica | Hypoxiaceae | Rhizome |
| 115. | Astragalusmembranaceus | Leguminosae | Root |
| 116. | Maytenusmacrocarpa | Celastraceae | Stembark |
| 117. | Cephalotaxus Harrington | Cephalotaxaceae | Entire |

Natural Dietary Remedies of Anti Cancer Agents

Natural dietary agents including fruits, vegetables, and spices have drawn a great deal of attention from both the scientific community and the general public owing to their demonstrated ability to suppress cancers. Recent studies suggest that the consumption of food rich in fruits, vegetables and spices have a lower incidence of cancers (stomach, esophagus, lung, oral cavity and pharynx, endometrium, pancreas and colon). Dietary agents consist of a wide variety of biologically active components that are responsible for the anti-cancer effects like curcumin, genistein, resveratrol, diallylsulfide, S-allyl cysteine, allicin, lycopene, capsaicin, diosgenin, gingerol, ellagic acid, ursolic acid, silymarin, anethol, catechins, eugenol, isoeugenol, dithiolthiones, isothiocyanates, indole-3-carbinol, isoflavones, saponins, phytosterols, inositol hexaphosphate, Vitamin C, D-limonene, lutein, folic acid, beta carotene, selenium, Vitamin E and flavonoids. Many of which have been used

in traditional medicines for thousands of years. These dietary agents are believed to suppress the inflammatory processes that lead to transformation, hyperproliferation, and initiation of carcinogenesis. Their inhibitory influences may ultimately suppress the final steps of carcinogenesis i.e angiogenesis and metastasis (Table 2)

Table 2: Dietary sources as anticancer agent^[32]

| S. No. | Botanical Name | Family | Source | Compound |
|--------|---|---------------------------|----------------------|------------------------------|
| 1 | Carica papaya, | Caricaceae | Berries | -Cryptoxanthin |
| 2 | Glycyrrhizaglabra; Glycyrrhiza radix; Glycyrrhizauralensis, | Leguminosae | Licorice root | Glycyrrhizin |
| 3 | Cannabis sativa | Cannabiaceae | Hemp | Cannabinol |
| 4 | Rosmarinusofficinalis | Lamiaceae | Rosemary | Carnosol |
| 5 | Puerarialobata radix | Fabaceae | | Genistein |
| 6 | Glycine max | Fabaceae | Soybeans | Genistein |
| 7 | Prunusarmeniaca | Rosaceae | Apricots | Carotenoids |
| 8 | Zingiberofficinale | Zingiberaceae | Tuber | Gingerol |
| 9 | Lycopersiconesulentum | Solanaceae | Tomato | Lycopene, Lutein, Kaempferol |
| 10 | Piper nigrum; Piper longum | Piperaceae | Black pepper | Purpurogallin; Piperine |
| 11 | Ocimum sanctum | Lamiaceae | Basil | Ursolic acid |
| 12 | Betula alba | Betulaceae | Birch tree | Betulinic acid |
| 13 | Crocus sativus | Iridaceae | Saffron | Carotenoids |
| 14 | Silymarinmarianum | Asteraceae | Milk thistle | Silymarin |
| 15 | Capsaicum annum; Capsaicumfrutens | Solanaceae | Red chilli | Capsaicinoids, Capsaicin |
| 16 | Camellia sinensis | Theaceae | Green and black teas | Catechin and theaflavins |
| 17 | Vitisvinifera | Vitaceae | Grapes | Resveratrol |
| 18 | Daucuscarotasativus | Apiaceae/umbel liferae | Carrot | -Carotene |
| 19 | Tabebuiaavellanadae | Bignoniaceae | Lapacha tree | Lapachone |
| 20 | Citrus aurantium | Rutaceae | Orange | Hesperidin |
| 21 | Prunusdulcis | Rosaceae | Almond | Morin |
| 22 | Aloe arborescens | Asphodelaceae | Aloe vera | Emodin |
| 23 | Opium poppy | Papaveraceae | Poppy | Morphine and its analogues |
| 24 | Curcubitamoschata | Cucurbitaceae | Pumpkin | -Carotene |
| 25 | Azadirachataindica | Meliaceae | Neem | Polyphenolics |

Marine Remedies as Source of Anti-Cancer Agents

Marine organisms are a rich source for natural products^[40]. In recent time, advancement in deep-sea collection and aqua culture technology gives significant number of compounds derived from marine organisms entering preclinical and early clinical evaluation as potential anticancer agent^[41, 42]. Overall, more than 3000 new substances have been identified from marine organisms that demonstrate the great potential as a source of novel chemical classes^[43]. Marine belongs to very diverse structural classes including polyketides, terpenes, steroids and peptides. The organisms yielding these bioactive marine compounds include invertebrate animals, algae, fungi and bacteria^[44].

The first anticancer product didemnin B, a cyclic depsipeptide isolated from the tunicate *Trididemnum solidum* from marine source enter in clinical trials. Preliminary results showed a partial activity against non-Hodgkin's lymphoma^[45]. It can inhibit protein synthesis and arrest G1 phase of cell-cycle. Another depsipeptide Aplidine appear to be more active as comparison with didemninB in preclinical trial and does not produce life-threatening neuromuscular toxicity. Preclinical data indicate that aplidine is active against several tumors through blockade of cell-cycle progression at G1 phase^[46]. There are number of ecteinascidins have been isolated from the marine source tunicate *Ecteinascidia turbinata*. One of these ecteinascidins (ET-743) was selected for clinical trials and antitumor effects have been observed in phase I studies^[47]. ET-743 is a tetrahydroisoquinilone alkaloid and they acts by selective alkylation of guanine residues in the DNA minor groove^[48] and also interacts with nuclear

proteins^[49]. In Europe and the United States ET-743 is currently in phase II clinical trials^[47]. The dolastatins are a class of peptides obtained from the Indian Ocean, *Dolabellaauricularia*. These peptides have cytotoxic activity and now a day, dolastatin10 and dolastatin15 of this class have received the greatest clinical interest. Dolastatin10 has entered in Phase I and Phase II clinical trials, after showing significant antitumor activity in preclinical models^[50]. Its mechanism of action involves inhibition of microtubule assembly ultimately result in cell-cycle arrest in metaphase^[51, 52]. The bryostatins, 20 macrocyclic lactones isolated from *Bugulaneritina* and other marine bryozoa. These macrocyclic compounds have shown significant activity against lymphocytic leukemia cell line^[53]. Bryostatin1 has recently entered phase II clinical trials for the treatment of melanoma, non-Hodgkin's lymphoma, renal cancer and colorectal cancer^[54-56] and continues to be evaluated in phase I clinical trials. Bryostatin1 has been found to promote the normal growth of bone marrow progenitor cells, to provide in vivo protection against normally lethal doses of ionizing radiation and to serve as an immune stimulant, enhancing the normal production of interleukin2 and interferons^[57].

Beside this there are the number of compounds isolated from marine as potential anti-cancer agents included in Table 3^[59, 58]

Table 3: Marine derived potential anticancer agent.^[32]

| S.No. | Compound | Organism | Chemistry | Mechanism of action |
|-------|--------------------------|--------------|----------------------|--|
| 1. | Aaptamine | Sponge | Alkaloid | Induction of p21 and G2/M cell cycle arrest |
| 2. | Cortistatin A | Sponge | Alkaloid | Selective inhibition of angiogenesis |
| 3. | Aplidine | Ascidian | Depsipeptide | Oxidation and inactivation of low molecular weight-protein tyrosine phosphatase activity |
| 4. | Bastadine 6 | Sponge | Alkaloid | Inhibition of angiogenesis in vitro and in vivo involves apoptosis |
| 5. | Fucoxanthinol | Ascidian | Carotenoid | Induction of apoptosis |
| 6. | Lamellarin D | Mollusk | Alkaloid | ErbB3 protein and PI3K- Akt pathway involved in necrosis induction |
| 7. | Clavulone II | Soft coral | Prostanoid | G1 cell cycle arrest and apoptosis |
| 8. | Geodiamolides | Sponge | Peptide | Disorganization of actin filaments |
| 9. | Ircinin-1 | Sponge | Sesterterpene | G1 phase inhibition and apoptosis induction |
| 10. | Laxaphycins A and B | Bacterium | Cyclic peptides | Increased polyploidy by putative topoisomerase II alterations |
| 11. | Leptosins C and F | Fungus | Alkaloid | DNA topoisomerase I and II inhibition and apoptosis induction |
| 12. | Onnamide A | Sponge | Polyketide | Protein synthesis inhibition |
| 13. | Phillinopside A | Sea cucumber | Saponin | Inhibition of angiogenesis and receptor tyrosine kinases |
| 14. | Variolin B | Sponge | Alkaloid | Inhibition of cyclin-dependent kinases and apoptosis induction |
| 15. | Aplidine | Ascidian | Depsipeptide | Induction of apoptosis with concomitant G1 arrest and G2 blockage |
| 16. | Ascididemin | Ascidian | Alkaloid | Direct iminoquinone reduction and reactive oxygen species generation |
| 17. | Cammbrescidin 800 | Sponge | Alkaloid | Induction of erythroid differentiation and cell cycle arrest |
| 18. | Dideoxypetrosynol A | Sponge | Fatty acid | Induction of apoptosis via mitochondrial signaling pathway |
| 19. | Dolastatin 10 | Mollusc | Peptide | Binds to amino-terminal peptide of α -tubulin containing cysteine |
| 20. | Girolline | Sponge | Alkaloid | Induction of G2/M cell cycle arrest and p53 proteasome recruitment |
| 21. | Halichondrin B analogues | Sponge | Macrolide derivative | Induction of mitotic blockage and apoptosis |
| 22. | Lissoclinolide | Ascidian | Fatty acid | G2/M cell cycle arrest |
| 23. | Neoamphimedine | Sponge | Alkaloid | Induction of topoisomerase II α -mediated catenation of DNA |
| 24. | Psammaplin A | Sponge | Alkaloid | Inhibition of aminopeptidase N and |

| | | | | |
|-----|------------------------|----------|-----------------------|---|
| | | | | suppression of angiogenesis in vitro |
| 25. | Alkylpyridinium | Sponge | Alkaloid | Induction of apoptosis and reduced cell adhesion |
| 26. | Aeropysinin | Sponge | Alkaloid | Induction of apoptosis on proliferating endothelial cells |
| 27. | Bryostatin-1 | Bryozoan | Macrolide | Potential of ara-C induced apoptosis by PKC-dependent release of TNF- |
| 28. | Cephaiostatin | Worm | Steroid | Apoptosis and increased mitochondrial matrix density |
| 29. | Chondropsin A | Sponge | Macrolide | In Vitro inhibition of V-ATPase enzyme |
| 30. | Dehydrothrysirol | Alga | Triterpene | Enhanced apoptosis induction in estrogen receptor negative breast cancer cells |
| 31. | Diazonamide-A | Ascidian | Peptide | Disruption of mitosis and cellular microtubules with inhibition of GTP hydrolysis |
| 32. | Dictyostatin | Sponge | Polyketide | Induction of tubulin polymerization |
| 33. | Dolastatin 11 | Mollusc | Peptide | F-actin stabilization by connection between two long-pitch strands |
| 34. | Ecteinascidin-743 | Ascidian | Isoquinoline alkaloid | Telomere dysfunction increases susceptibility to ET-743 |
| 35. | GA3 polysaccharide | Alga | Polysaccharide | Inhibition of topoisomerase I and II |
| 36. | Hemiassterlin analogue | Sponge | Tripeptide | Induction of microtubule depolymerisation |
| 37. | Kahalalide F | Mollusc | Depsipeptide | Potent cytotoxicity and induction of necrosis |
| 38. | Lamellarin D | Mollusc | Alkaloid | Potent inhibition of topoisomerase I |
| 39. | omega-3 fatty acids | Fish | Fatty acid | -- |

Microorganisms as Source of Anti-Cancer Agents

Antitumor antibiotics are among the most important cancer chemotherapeutic agents, and include members of the anthracycline, bleomycin, actinomycin, mitomycin and aureolic acid families^[6]. Clinically useful agents from these above families are the daunomycin and related agents like doxorubicin, idarubicin and epirubicin; the peptolides (exemplified by dactinomycin), the mitosanes (such as mitomycin C) and the glycosylated anthracenonemithramycin. The anthracyclines are among the most used antitumor antibiotics in the clinic and exert antitumor activity mainly by inhibiting topoisomerase II^[60,61]. Wortmannin is a product of the fungus *Talaromyces wortmanni* and inhibits signal transduction pathways by forming a covalent complex with an active-site residue of phosphoinositide 3 kinase (PI3K), inhibiting PI3K activity^[62]. Thus, toxins that originally evolved to kill competing microorganisms can have a variety of physiological effects in animals. In many cases, the targets of these compounds are components of signal transduction cascades that are conserved in many species, and that have been considered novel targets for anticancer drug discovery (Table 4)^[63]

Table 4: Microorganism derived anti-cancer agents.^[32]

| S.No. | Compound | Microorganism | Used in Cancer |
|-------|-------------|-------------------------------------|--|
| 1. | Actinomycin | <i>Streptomyces</i> spp. | Sarcoma and germ-cell tumors |
| 2. | Bleomycin | <i>Streptomyces verticillus</i> | Germ-cell, cervix and head and neck cancer |
| 3. | Daunomycin | <i>Streptomyces coeruleorubidus</i> | Leukemia |
| 4. | Doxorubicin | <i>Streptomyces Pnuceticus</i> | Lymphoma, breast, ovary, lung and sarcomas |
| 5. | Epirubicin | <i>Streptomyces pnuceticus</i> | Breast cancer |
| 6. | Idarubicin | <i>Streptomyces Pnuceticus</i> | Breast cancer and leukemia |
| 7. | Mitomycin C | <i>Streptomyces caespitosus</i> | Gastric , colorectal, anal and lung |

| | | | cancer |
|-----|--------------|----------------------------|--------------|
| 8. | Geldanamycin | Streptomyces Hygroscopicus | Experimental |
| 9. | Rapamicin | Streptomyces hygroscopicus | Experimental |
| 10. | Wortamannin | Talaromyceswortmanni | Experimental |

2. Conclusion

According to World Health Organisation, 80% of people living in the rural areas depend on medicinal plants as primary health care system. These practices are solely based on the knowledge of traditional use of herbal remedies, natural dietary remedies, marine remedies and micro-organism as a source of medicine. These products are formulated to generate different types of effective drugs to enhance anti-cancer activities. This review revealed that many of medicinal plants used by traditional healer are reported to have scientific evidence. All the natural products discussed in this review exhibit anticancer activities. Natural products offer a great opportunity to evaluate not only totally new chemical classes of anticancer agents, but also novel and potentially relevant mechanisms of action.

3. Acknowledgement

I am cordially grateful to my Parents and my esteemed respected guide Dr. (Prof.) ShaliniTripathi, Department of Pharmacy, Rameshwaram Institute of Technology and Management for her supervision, advice and guidance from the very early stage of this research as well as giving me extraordinary experiences throughout the work.

4. References

1. Department of Health and Human Services. Agency for Toxic Substances and Disease Registry. Cancer Fact Sheet. Accessed at www.atsdr.cdc.gov/COM/cancer-fs.html on August 10, 2012.
2. National Cancer Institute. Cancer: Questions and Answers. Accessed at www.cancer.gov/cancertopics/factsheet/Sites-Types/general on December 18, 2009.
3. NarahMerina, kalicajogen Chandra and kotokyjibon medicinal and plants with potential anti-cancer activity: Areview. International research journal of pharmacy.2012, 26-30
4. Ashworth A, Christopher Lj, Reis-Filho S. Genetic Interactions in cancer progression and Treatment. *Cell* 2011; 145(1):30-38.
5. "Cancer Glossary". *Cancer.org*. American Cancer Society. Retrieved September 11, 2013.
6. "What is cancer?". *Cancer.gov*. National Cancer Institute. Retrieved September 11, 2013.
7. Hanahan, Douglas; Weinberg, Robert A. (January 7, 2000). "The hallmarks of cancer". *Cell***100** (1): 57–70.
8. Hanahan, Douglas; Weinberg, Robert A. (2011). "Hallmarks of Cancer: The Next Generation". *Cell***144** (5): 646–74.
9. Varricchio, Claudette G. (2004). A cancer source book for nurses. Boston: Jones and Bartlett Publishers. p. 229
10. Anand P, Kunnumakkara AB, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB (September 2008). "Cancer is a preventable disease that requires major lifestyle changes". *Pharm. Res.* 25 (9): 2097–116.
11. Kravchenko J, Akushevich I, Manton, KG (2009). Cancer mortality and morbidity patterns in the U. S. population: an interdisciplinary approach. Berlin: Springer. ISBN 0-387-78192-7.
12. DeVita VT Jr, Serpick AA, and Carbone PO. Combination chemotherapy in the treatment of advanced Hodgkin's disease. *Ann Intern Med.* 1970; 73:881-895.
13. Noble RL. The discovery of the vinca alkaloids – chemotherapeutic agents against cancer. *Biochem Cell Biol.* 1990; 68:1344-1351.
14. Stähelin H. Activity of a new glycosidic lignan derivative (VP-16-213) related to podophyllotoxin in experimental tumors. *Eur J Cancer.* 1973; 9:215-221.
15. Harvey AL. Medicines from nature: are natural products still relevant to drug discovery. *Trends Pharmacol Sci.* 1999; 20:196-198.
16. Liu LF. DNA topoisomerase poisons as antitumor drugs. *Annu Rev Biochem.* 1989; 58:351-375.
17. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from *Taxusbrevifolia*. *J Am Chem Soc.* 1971; 93:2325-2327.
18. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer. *J ClinOncol.* 1996; 14:3056-3061.
19. Bertino JR. Irinotecan for colorectal cancer. *SeminOncol.* 1997; 24:S18-S23.
20. Liu LF, Desai SD, Li TK, et al. Mechanism of action of camptothecin. *Ann New York Acad Sci.* 2000; 922:1-10.
21. Harmon AD, Weiss U, Silvertown JV. The structure of rohutukine, the main alkaloid of *Amoorarohituka* (syn. *Aphanamixispolystachya*) (Maliaceae). *Tetrahydron.* 1979; 20:721-724.

22. Cragg G, Suffness M. Metabolism of plant-derived anticancer agents. *PharmacolTher.* 1988; 37:425-432.
23. Losiewicz MD, Carlson BA, Kaur G, et al. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. *BiochemBiophys Res Commun.* 1994; 201:589-595.
24. Worland PJ, Kaur G, Stetler-Stevenson M, et al. Alteration of the phosphorylation state of p32cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. *BiochemPharmacol.* 1993; 46:1831-1836.
25. Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. *Ex OpinInv Drugs.* 2000; 9:2903-2911.
26. Powell RG, Weisleder D, Smith CR Jr, et al. Structures of harringtonine, isoharringtonine, and homoharringtonine. *TetrahydronLett.* 1970; 11:815-818.
27. Zhou DC, Zittoun R, Marie JP. Homoharringtonine: an effective new natural product in cancer chemotherapy. *Bull Cancer.* 1995; 82:987-995.
28. Kantarjian HM, O'Brien S, Anderlini P, et al. Treatment of myelogenous leukemia: current status and investigational options. *Blood.* 1996; 87:3069-3081.
29. Rowinsky EK, Noe DA, Ettinger DS, et al. Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. *Cancer Res.* 1993; 53:1794-1801.
30. Rehm S, Devor DE. Acute effects of 4-ipomeanol on experimental lung tumors with bronchiolar or alveolar cell features in Syrian hamsters or C3H/HeNCr mice. *J Cancer Res ClinOncol.* 1993; 120:41-50.
31. Li YZ, Li CJ, Pinto AV, et al. Release of mitochondrial cytochrome c in both apoptosis and necrosis induced by -lapachone in human carcinoma cells. *Mol Med.* 1999; 4:232-239.
32. Noolvi N Malleshappa, sharmarohini, Bhanotabhishek. Natural sources as potential anti-cancer agents: A review. *International Journal of Phytomedicine* 3 (2011) 09-26
33. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. *Nutr Cancer.* 1992; 18(1):1-29.
34. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer prevention: a review. *J Am Diet Assoc.* 1996; 96(10):1027-39.
35. Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: a global perspective. *PharmacolTher.* 2003; 99(1):1-13.
36. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. *BiochemPharmacol.* 2006; 71:1397-1421.
37. Hoyoku N, Michiaki M, Harukuni T, et al. Cancer prevention by carotenoids. *Arch BiochemBiophys.* 2009; 483 : (2):165-168.
38. Pomponi AS. The bioprocess-technological potential of the sea. *J Biotechnol.* 1999; 70:5-13.
39. Schwartzmann G. Marine organisms and other novel natural sources of new anticancer drugs. *Ann Oncol.* 2000; 11:235-243.
40. Schwartzmann G, Rocha AB, Berlinck R, et al. Marine organisms as a source of new anticancer agents. *Lancet Oncol.* 2001; 2:221-225.
41. Schweitzer J, Handley FG, Edwards J, et al. Summary of the workshop on drug development, biological diversity, and economic growth. *J Natl Cancer Inst.* 1991; 83:1294-1298.
42. Rinehart KL. Antitumor compounds from tunicates. *Med Res Rev.* 2000; 20:1-27.
43. Chun HG, Davies B, Hoth D, et al. Sufness. Didemnin B The first marine compound entering clinical trials as an antineoplastic agent. *Invest New Drugs.* 1986; 4:279-284.
44. Geldof AA, Mastbergen SC, Henrar REC, et al. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using invitro assays. *Cancer ChemotherPharmacol.* 1999; 44:312-318.
45. Demetri G, Garcia-Carbonero R, Harmon D, et al. Ecteinascidin-743 (ET-743) induces objective responses and disease control in patients with advanced non-osseous sarcomas: results from phase II trials. *Ann Oncol.* 2000; 11(Suppl 4):126.
46. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. *Eur J Cancer.* 2001; 37:97-105.
47. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. *Int J Cancer.* 2001; 92:583-588.
48. Poncet J. The dolastatins, a family of promising antineoplastic agents. *Curr Pharm Des.* 1999; 5:139-162.
49. Bai R, Pettit GR, Hamel E. Dolastatin10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. *BiochemPharmacol.* 1990; 39:1941-1949.
50. Pathak S, Multani AS, Ozen M, et al. Dolastatin10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line. *Oncol Res.* 1998; 5:373-376.
51. Pettit GR. The bryostatins. *FortschrChem Org Naturst.* 1991; 57:153-195.

52. Pagliaro L, Daliani D, Amato R, et al. Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. *Cancer*. 2000; 89:615-618.
53. Varterasian ML, Mohammad RM, Shurafa MS, et al. Phase II trial of bryostatin1 in Patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. *Clin Cancer Res*. 2000; 6:825-828.
54. Zonder JA, Shields AF, Zalupski M, et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. *Clin Cancer Res*. 2001; 7:38-42.
55. Ahmad I, Al-Katib AM, Beck FW, et al. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin1 followed by 2-chlorodeoxyadenoside: case report. *Clin Cancer Res*. 2000; 6:1328-1332.
56. Mayer A and Gustafson KR. Marine pharmacology in 2002–2004: Anti-tumour and cytotoxic compounds. *Eur J Cancer*. 2006; 42:2241–2270.
57. Mayer A and Gustafson K R. Marine pharmacology in 2005–2006: Anti-tumour and cytotoxic compounds. *Eur J Cancer*. 2008; 44: 2257–2287.
58. Binascchi M, Farinosi R, Borgnetto ME, et al. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II poisoning anthracyclines. *Cancer Res*. 2000; 60:3770-3776.
59. Patrick Y. Major microbial diversity initiative recommended. *Am SocMicrobiol News*. 1997; 63:417-421.
60. Alberts MW, Williams RT, Brown EJ, et al. KBP-Rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. *J Biol Chem*. 1993; 268:22825-22829.
61. Schulte TW, Neckers LM. The benzoquinone ansamycin17-allylamino-17 demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. *Cancer ChemotherHarmacol*. 1998; 42:273-279.
62. Cadenas ME, Sandfrison A, Cutler NS, et al. Signal transduction cascades as targets for therapeutic intervention by natural products. *Trends Biotechnol*. 1998; 16:427-433.
63. Adjei AA. Signal transduction pathway targets for anticancer drug discovery. *CurrPharmaceut Design*. 2000; 6:361-378.
64. www.Wikipedia, the free encyclopedia.htm